Attached files
| file | filename |
|---|---|
| 10-K - FORM 10-K - NEKTAR THERAPEUTICS | f57959e10vk.htm |
| EX-10.3 - EX-10.3 - NEKTAR THERAPEUTICS | f57959exv10w3.htm |
| EX-21.1 - EX-21.1 - NEKTAR THERAPEUTICS | f57959exv21w1.htm |
| EX-31.1 - EX-31.1 - NEKTAR THERAPEUTICS | f57959exv31w1.htm |
| EX-31.2 - EX-31.2 - NEKTAR THERAPEUTICS | f57959exv31w2.htm |
| EX-32.1 - EX-32.1 - NEKTAR THERAPEUTICS | f57959exv32w1.htm |
| EX-10.7 - EX-10.7 - NEKTAR THERAPEUTICS | f57959exv10w7.htm |
| EX-10.12 - EX-10.12 - NEKTAR THERAPEUTICS | f57959exv10w12.htm |
| EX-10.31 - EX-10.31 - NEKTAR THERAPEUTICS | f57959exv10w31.htm |
| EX-10.22 - EX-10.22 - NEKTAR THERAPEUTICS | f57959exv10w22.htm |
| EX-10.28 - EX-10.28 - NEKTAR THERAPEUTICS | f57959exv10w28.htm |
| EX-10.16 - EX-10.16 - NEKTAR THERAPEUTICS | f57959exv10w16.htm |
| EX-10.15 - EX-10.15 - NEKTAR THERAPEUTICS | f57959exv10w15.htm |
| EX-10.14 - EX-10.14 - NEKTAR THERAPEUTICS | f57959exv10w14.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent
to the incorporation by reference in the following Registration Statements:
(1) Registration
Statements (Form S-3 Nos. 333-54080, 333-108859, 333-120009, 333-67340, 333-130591
and 333-171747) of Nektar Therapeutics; and
(2) Registration
Statements (Form S-8 Nos. 333-07969, 333-59735, 333-65919, 333-74669, 333-32788,
333-54078, 333-55032, 333-67342, 333-71936, 333-76638, 333-98321, 333-103040, 333-117975,
333-136498, 333-145259, 333-153106 and 333-170371) pertaining to the amended and restated 1994
Equity Incentive Plan, the 1998 Non-Officer Equity Incentive Plan, the 2000 Non-Officer Equity
Incentive Plan, the 401(k) Retirement Plan, the Employee Stock Purchase Plan, the 2000 Equity
Incentive Plan, the 2008 Equity Incentive Plan, the Bradford Particle Design plc Share Option
Schemes, and the Shearwater Corporation 1996 Nonqualified Stock Option Plan, of Nektar
Therapeutics;
of our reports dated March 1, 2011, with respect to the consolidated financial statements and
schedule of Nektar Therapeutics and the effectiveness of internal control over financial reporting
of Nektar Therapeutics included in this Annual Report (Form 10-K) for the year ended December 31,
2010.
/s/ Ernst & Young LLP
Palo Alto, California
March 1, 2011
March 1, 2011
100